RSV vaccine effective in cutting hospitalisation among older adults

Embargoed until: Publicly released: 2024-09-05 01:00

International

CC-0. https://pixabay.com/photos/medical-appointment-doctor-563427/

US scientists say the respiratory syncytial virus (RSV) vaccine reduces the likelihood of adults over 60 being hospitalised if they catch the virus. Their analysis of 2,978 people, 367 of whom had RSV, found the vaccine was 75% effective in preventing hospitalisation across all the ages studied, even for people over 75. The authors say between 60,000 and 160,000 people are hospitalised with RSV in the USA every year, and the results show the vaccine is effective in preventing hospitalisation in older people who are at high risk of severe RSV.

Media release

From: JAMA

RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older

About The Study: Among adults age 60 years and older in 19 U.S. states, respiratory syncytial virus (RSV) vaccination was associated with a reduced likelihood of hospitalization with RSV compared with no vaccination. These findings expand upon prelicensure trial results in 2 ways. First, they provide evidence of vaccine protection against RSV-associated hospitalization, of which an estimated 60,000 to 160,000 occur annually among U.S. adults age 65 years and older. Second, they demonstrate protection in a population that more closely represents those at high risk of severe RSV disease, including adults age 75 years and older and those with immunocompromising conditions.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA

Research:Paper

Organisation/s: Centers for Disease Control and Prevention (CDC), USA

Funder: This work was funded by the CDC (contract 75D30122C14944 to Vanderbilt University Medical Center).

Media Contact/s

Contact details are only visible to registered journalists.